GT Biopharma, Inc. Announces 3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
| GTBP Stock | USD 2.36 0.10 4.07% |
Slightly above 63% of GT Biopharma's investor base is looking to short. The analysis of the overall investor sentiment regarding GT Biopharma suggests that many traders are alarmed. GT Biopharma's investing sentiment overview a quick insight into current market opportunities from investing in GT Biopharma. Many technical investors use GT Biopharma stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
GTBP |
BRISBANE, CALIFORNIA, May 21, 2024 -- GT Biopharma, Inc. , today announced that it has entered into a...
Read at globenewswire.com
 |
GT Biopharma Fundamental Analysis
We analyze GT Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GT Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GT Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
GT Biopharma is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
GT Biopharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with GT Biopharma stock to make a market-neutral strategy. Peer analysis of GT Biopharma could also be used in its relative valuation, which is a method of valuing GT Biopharma by comparing valuation metrics with similar companies.
Peers
GT Biopharma Related Equities
| ALLR | Allarity Therapeutics | 9.86 | ||||
| SRZN | Surrozen | 7.48 | ||||
| CVKD | Cadrenal Therapeutics, | 2.25 | ||||
| PRAX | Praxis Precision | 2.24 | ||||
| SONN | Sonnet Biotherapeutics | 1.33 | ||||
| AKTX | Akari Therapeutics | 1.10 | ||||
| BDRX | Biodexa Pharmaceticals | 0.87 | ||||
| MNPR | Monopar Therapeutics | 0.58 | ||||
| SABS | SAB Biotherapeutics | 0.57 | ||||
| TARA | Protara Therapeutics | 0.57 | ||||
| ANEB | Anebulo Pharmaceuticals | 1.60 | ||||
| PULM | Pulmatrix | 1.69 | ||||
| VRAX | Virax Biolabs | 2.31 | ||||
| QNRX | Quoin Pharmaceuticals | 3.13 | ||||
| VRPX | Virpax Pharmaceuticals | 4.00 | ||||
| REVB | Revelation Biosciences | 5.01 |
Additional Tools for GTBP Stock Analysis
When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.